Compare Deere & Company (DE) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Tenet Healthcare Corporation — how do they compare? Deere & Company trades at $652.58 (market cap $177.11B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Deere & Company is far larger — about 8.5× Tenet Healthcare Corporation's market cap, and Deere & Company pays a 0.99% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Tenet Healthcare Corporation for 15 Days on average.
| DE | THC | |
|---|---|---|
Market Cap | $177.11B | $20.92B |
Volume | 1,206,308 | 455,764 |
Sector | Industrials | Health |
52-Week High | $709.48 | $280.77 |
52-Week Low | $439.11 | $161.37 |
Typical Hold Time | 75 Days | 15 Days |
Enterprise Value | $231.01B | $32.00B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $652.58, down 4.42% today, showing bearish technical signals with support at $643 and resistance at $658. The company maintains strong profitability with a 10.39% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Deere's AI initiatives and institutional buying interest, though revenue has declined from 2023 peaks.
Deere presents a mixed outlook with solid fundamentals and analyst support (43.48% buy rating, $731.20 target) but faces agricultural cycle headwinds and competitive pressures. The stock offers potential upside from AI-driven farming solutions but risks include cyclical demand volatility and high debt levels at 60.31% of assets.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
